To view the PDF file, sign up for a MySharenet subscription.

MEDICLINIC INTERNATIONAL PLC - Transactions by persons discharging managerial responsibilities and persons closely associated with them

Release Date: 25/05/2022 14:00
Code(s): MEI     PDF:  
Wrap Text
Transactions by persons discharging managerial responsibilities and persons closely associated with them

Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
LEI: 2138002S5BSBIZTD5I60
(‘Mediclinic’, the ‘Company’, or the ‘Group’)

25 May 2022


  1.      Details of PDMR / persons closely associated with them (‘PCA’)

  a)      Name                      Thomas Singer

  2.      Reason for the notification

  a)      Position / status         Non-executive Director – Mediclinic International plc

  b)      Initial notification /    Initial notification
  3.      Details of the issuer, emission allowance market participant, auction platform, auctioneer or
          auction monitor

  a)      Name                      Mediclinic International plc

  b)      LEI                       2138002S5BSBIZTD5I60

  4.      Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
          type of transaction; (iii) each date; and (iv) each place where transactions have been

  a)      Description of the        Ordinary 10p shares
          financial instrument

          Identification Code       GB00B8HX8Z88

  b)      Nature of the             Purchase of shares

  c)      Price(s) and
          volume(s)                 Price(s)                          Volume(s)
                                    366.00 pence                      20 000

  d)      Aggregated

          Aggregated volume         20 000

          Price                     366.00 pence per share

  e)      Date of the               25 May 2022

  f)      Place of the              London Stock Exchange

About Mediclinic International plc

Mediclinic is a diversified international private healthcare services group, established in South Africa
in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the UAE.

The Group’s core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and trusted
provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare
in each of its markets.

At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 20 day case clinics and 20 outpatient clinics. The Swiss operations included 17 hospitals
and four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50
hospitals (three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day
case clinics (four of which operated by Intercare) across South Africa, and around 8 650 inpatient
beds; and the UAE operated seven hospitals, two day case clinics and 20 outpatient clinics with
around 1 000 inpatient beds in the UAE. In addition, under management contract the UAE will open a
200-bed hospital in the Kingdom of Saudi Arabia in 2023.

The Company’s primary listing is on the London Stock Exchange (‘LSE’) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare
group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930

Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181

Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000

Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

Date: 25-05-2022 02:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story